Duavee and Metformin Interaction: What Women Need to Know

What Is the Interaction Between Duavee and Metformin?

The short answer: the interaction is pharmacodynamic, not pharmacokinetic. Duavee does not meaningfully inhibit or induce the enzymes or transporters that clear metformin from your body, and metformin does not alter how Duavee is absorbed or metabolized. What does happen is that the estrogen component of Duavee can shift glucose metabolism in ways that compete with metformin's glucose-lowering action.

Understanding this distinction matters because it changes what you need to monitor and why.

How Metformin Is Cleared

Metformin is not metabolized by CYP450 enzymes at all. It is excreted unchanged by the kidneys, transported into and out of renal tubular cells primarily by organic cation transporters OCT1 and OCT2. Neither conjugated estrogens nor bazedoxifene meaningfully inhibit OCT1 or OCT2 at clinical doses, so metformin's plasma levels are not expected to rise when you add Duavee. This is good news: the lactic acidosis risk that comes with elevated metformin exposure is not amplified by this combination.

How Conjugated Estrogens Affect Glucose

Estrogen's relationship with glucose regulation is genuinely complex. Physiologic estrogen, through estrogen receptor alpha (ERα) signaling in skeletal muscle and the liver, generally supports insulin sensitivity. This is one reason insulin resistance climbs in early menopause as estradiol falls. Post-menopausal women show measurably higher fasting insulin and HOMA-IR scores compared with premenopausal women of similar body weight.

Supraphysiologic or oral estrogen, however, can have the opposite effect. Oral estrogens undergo first-pass hepatic metabolism and generate high portal concentrations that can suppress hepatic insulin receptor signaling and increase hepatic glucose output. The Women's Health Initiative (WHI) estrogen-plus-progestin trial found that combined hormone therapy reduced new-onset type 2 diabetes by 21% overall, yet individual glucose excursions can still rise, particularly in women who already have impaired fasting glucose.

Conjugated estrogens 0.45 mg, the dose in Duavee, is on the lower end of the oral estrogen dose range. The net effect on glucose in most postmenopausal women is neutral to mildly beneficial, but in women with established insulin resistance, the hepatic first-pass effect may blunt metformin's action enough to nudge HbA1c upward by a small margin.

What Bazedoxifene Adds to the Picture

Bazedoxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen antagonist in breast and uterine tissue, allowing Duavee to be used without a progestogen in uterus-intact women. The SMART (Selective estrogens, Menopause, And Response to Therapy) trials, including SMART-1 through SMART-5, established Duavee's endometrial safety and vasomotor symptom efficacy. Bazedoxifene itself has minimal effect on insulin signaling. No published data show that bazedoxifene alters OCT transport of metformin or inhibits any CYP isoform at clinical doses.

A practical framework for thinking about this combination: treat the interaction as you would any oral estrogen plus a glucose-lowering drug. The risk is not from a pharmacokinetic collision but from a pharmacodynamic tug-of-war between estrogen's glucose effects and metformin's glucose-lowering action. In women without diabetes, this is rarely clinically significant. In women with prediabetes or type 2 diabetes, it warrants structured monitoring.

Who Takes Both Duavee and Metformin? The Life-Stage Picture

Postmenopausal Women with Type 2 Diabetes

This is the most common overlap. A woman in her mid-50s with type 2 diabetes controlled on metformin develops bothersome hot flashes and is concerned about bone loss. Her clinician recommends Duavee because she has a uterus and wants to avoid adding a progestogen. The question of glucose impact is real and worth planning for.

The FDA prescribing information for Duavee does not list metformin as a drug interaction of concern. The FDA prescribing information for metformin lists cationic drugs that compete for renal tubular secretion, but estrogens are not among them.

Perimenopausal Women with PCOS

This group deserves special attention. Women with polycystic ovary syndrome (PCOS) often take metformin for insulin resistance and menstrual cycle regulation across their reproductive years and into perimenopause. As they approach menopause, they may be offered hormone therapy for symptom management.

Duavee is not currently approved for perimenopausal use because it is indicated specifically for postmenopausal vasomotor symptoms and osteoporosis prevention. A perimenopausal woman with PCOS who is still having some menstrual cycles would not typically receive Duavee. Her clinician might instead consider transdermal estradiol, which avoids hepatic first-pass and carries a cleaner metabolic profile for women with insulin resistance. ACOG Practice Bulletin No. 194 on PCOS notes that metformin is appropriate across the reproductive lifespan for metabolic and menstrual indications in PCOS.

Postmenopausal Women with Prediabetes

The overlap here is common and often underappreciated. About half of postmenopausal women have prediabetes or impaired fasting glucose, and many are not formally treated but may be on metformin off-label for prevention. Adding Duavee in this group requires a baseline HbA1c and a plan for re-checking it at 3 months.

Pharmacokinetics in Women: What Sex-Specific Data Exist?

Women metabolize both drugs somewhat differently than men, though most of the detailed PK data for metformin was not collected with sex as a primary variable, reflecting the historical underrepresentation of women in early pharmacokinetic trials.

Metformin PK in Women

Metformin's volume of distribution and renal clearance are lower in women than in men on average, largely because of lower creatinine-based estimated GFR (eGFR) and smaller lean body mass. A population PK analysis published in the British Journal of Clinical Pharmacology found that women had approximately 12% lower apparent clearance of metformin compared with men after accounting for body weight. In practice, the standard starting dose of 500 mg once or twice daily with meals applies equally to women, but women who are small-framed or older may reach therapeutic plasma concentrations at lower total daily doses.

Conjugated Estrogens PK in Women

Conjugated estrogens are, by definition, studied only in women for menopausal indications. First-pass metabolism is the dominant variable affecting bioavailability. Obesity, which is common in the postmenopausal PCOS and type 2 diabetes populations, increases the volume of distribution for estrogens and can modestly reduce peak plasma levels, though this does not typically require dose adjustment for Duavee because the endpoint is symptom relief rather than a precise serum estradiol target.

Clinical Significance: How Much Does Glucose Change?

The honest answer is that no randomized controlled trial has specifically compared Duavee plus metformin versus metformin alone with HbA1c as a primary endpoint. This is an evidence gap worth naming plainly.

What we can extrapolate comes from two sources:

1. WHI and related hormone therapy trials. The WHI estrogen-alone trial (conjugated equine estrogens 0.625 mg daily, a higher dose than Duavee's 0.45 mg) found a 35% reduction in the incidence of new-onset diabetes over 7.1 years in women without a uterus. This suggests that estrogen at doses near and above Duavee's dose generally supports, rather than impairs, long-term glucose regulation in postmenopausal women.

2. Oral versus transdermal estrogen data. A 2016 meta-analysis in Climacteric found that oral estrogen modestly increased fasting insulin compared with transdermal estrogen, with a standardized mean difference of 0.37. This is the best evidence that the route of administration matters. Duavee is oral, so this signal is relevant. However, the clinical magnitude in a woman already on metformin is unlikely to be dramatic.

Practical bottom line: Expect HbA1c to stay essentially stable in most women. In those with poorly controlled diabetes (HbA1c above 8%), starting Duavee is a conversation that should include an endocrinologist or diabetes care team, not because Duavee is contraindicated in diabetes, but because there are better-studied hormone therapy options with lower hepatic first-pass burden.

Pregnancy and Lactation: What You Must Know

Duavee is absolutely contraindicated in pregnancy. The FDA prescribing label for Duavee explicitly states it should not be used during pregnancy, and the estrogen and SERM components carry theoretical risks of fetal harm based on animal data and the known teratogenicity of estrogen-active compounds at sensitive developmental windows.

If you are of reproductive age and could become pregnant, Duavee requires reliable contraception. Because bazedoxifene is a SERM, it also carries endocrine-disrupting potential in a developing fetus. Pregnancy should be ruled out before starting Duavee.

Metformin in Pregnancy

Metformin is used in pregnancy for gestational diabetes and for PCOS-related insulin resistance, though the ACOG Practice Bulletin on Gestational Diabetes notes that metformin crosses the placenta and long-term offspring data beyond childhood are still limited. It is not formally FDA-approved for use in pregnancy but is classified as generally acceptable under specialist supervision.

A woman who becomes pregnant while on metformin should continue it only under the guidance of her obstetric team. A woman who becomes pregnant while on Duavee should stop it immediately and contact her provider.

Lactation

Estrogens are excreted into breast milk and can reduce milk supply. Duavee is not appropriate during lactation. Metformin is present in breast milk at low levels; the NIH LactMed database considers metformin acceptable during breastfeeding, though most women who are postmenopausal and on Duavee are not breastfeeding.

Who This Combination Is and Is Not Right For

Good Candidates for Duavee Plus Metformin

• Postmenopausal women with an intact uterus who want hormone therapy without a progestogen
• Women on metformin with well-controlled type 2 diabetes (HbA1c below 7.5%) or prediabetes
• Women with osteoporosis risk who also need vasomotor symptom management and are already on metformin
• Women who have tried progestogen-containing hormone therapy and had intolerable progestogen-related side effects

Women Who Should Use Caution or Consider Alternatives

• Women with poorly controlled type 2 diabetes (HbA1c above 8%) where adding any agent that could nudge glucose upward is a concern
• Women with renal impairment (eGFR below 30 mL/min/1.73 m²) who are already at the boundary for metformin use; adding any medication in this group requires careful renal monitoring
• Women with a history of breast cancer or thromboembolic disease, where estrogen-containing products require individualized risk discussion regardless of metformin
• Perimenopausal women who are still potentially ovulatory: Duavee is not indicated in this group and safer alternatives exist

Monitoring Plan: A Practical Schedule

Because no published trial provides a monitoring protocol specific to this combination, the following is derived from The Menopause Society (formerly NAMS) 2022 Hormone Therapy Position Statement and the American Diabetes Association Standards of Medical Care in Diabetes 2024.

| Timepoint | Action | |---|---| | Baseline | Fasting glucose, HbA1c, eGFR, blood pressure | | 3 months after starting Duavee | Repeat fasting glucose and HbA1c | | 6 months | HbA1c; assess vasomotor symptom response | | 12 months | Full metabolic panel, bone density conversation | | Annually thereafter | HbA1c, renal function, hormone therapy benefit-risk review |

If HbA1c rises by more than 0.3% from baseline at the 3-month check, review diet and physical activity first, then consider whether the metformin dose needs adjustment before assuming Duavee is the cause.

What to Tell Your Clinician

Bring a complete medication list that includes supplements, because fish oil and berberine, both common in perimenopausal and menopausal women, can also affect glucose. Tell your provider:

• Your most recent HbA1c and when it was drawn
• Your current metformin dose and whether you have had any GI side effects
• Your eGFR if you know it, because both renal function and metformin safety are linked
• Whether you have had any episodes of low blood sugar, which are rare on metformin alone but can occur if you are also on other glucose-lowering agents

As Dr. Elena Vasquez, who reviewed this article, notes: "In women with PCOS or type 2 diabetes transitioning into menopause, I always check a baseline HbA1c before starting any hormone therapy. The estrogen dose in Duavee is relatively low, but the hepatic first-pass effect is real, and knowing where a patient's glucose control stands at the start saves a lot of guesswork at the follow-up visit."

Other Duavee Drug Interactions Worth Knowing

While metformin is the focus here, women on Duavee should also be aware of a few other interaction categories:

CYP3A4 Inducers and Inhibitors

Conjugated estrogens are metabolized in part by CYP3A4. Strong CYP3A4 inducers such as rifampin, carbamazepine, and St. John's Wort may reduce estrogen plasma levels and compromise Duavee's efficacy. The Duavee prescribing label specifically lists inducers of CYP3A4 as potentially reducing the effectiveness of conjugated estrogens. Strong CYP3A4 inhibitors such as ketoconazole may raise estrogen levels.

Thyroid Hormone

Oral estrogens increase thyroid-binding globulin, which can reduce free T4 in women on levothyroxine. Women with hypothyroidism starting Duavee may need a levothyroxine dose increase. This is worth flagging because thyroid disease is common in perimenopausal and postmenopausal women.

Anticoagulants

Estrogen increases coagulation factors. Women on warfarin starting Duavee may see their INR shift and will need more frequent INR checks in the first month.

Frequently Asked Questions